Male breast carcinoma: increased awareness needed

被引:94
作者
White, Jonathan [2 ]
Kearins, Olive [3 ]
Dodwell, David [4 ]
Horgan, Kieran [2 ]
Hanby, Andrew M. [1 ]
Speirs, Valerie [1 ]
机构
[1] Univ Leeds, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England
[2] Gen Infirm, Dept Surg, Leeds LS1 3EX, W Yorkshire, England
[3] Univ Birmingham, W Midlands Canc Intelligence Unit, Birmingham B15 2TT, W Midlands, England
[4] St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England
关键词
RECEPTOR EXPRESSION; AROMATASE INHIBITOR; ENDOCRINE THERAPY; HORMONAL-THERAPY; CANCER PATIENTS; BRCA2; MUTATION; PROLACTIN; GYNECOMASTIA; FULVESTRANT; RISK;
D O I
10.1186/bcr2930
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Male breast carcinoma is a rare condition. Few male breast cancer-specific epidemiological or clinical trial data are available - our understanding of male breast cancer thus comes from studies of female breast cancer, painting an inaccurate picture when it comes to determining contributing factors. Clinicians report an increase in diagnoses of male breast cancer but this has not been formally reported. We therefore undertook a review of data obtained from four western nations: England, Scotland, Canada and Australia. When adjusted for age, this review clearly showed an increase in the incidence of male breast cancer over a 15-year period. Reasons for the increased incidence are discussed in the context of suggested risk factors such as BRCA2 and lifestyle changes over the past few decades. The clinical management of male breast carcinoma is considered, in particular the potential role of aromatase inhibitors and fulvestrant and targeting pathways involving prolactin and androgen receptor.
引用
收藏
页数:7
相关论文
共 62 条
[11]   Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer [J].
Callari, Maurizio ;
Cappelletti, Vera ;
De Cecco, Loris ;
Musella, Valeria ;
Miodini, Patrizia ;
Veneroni, Silvia ;
Gariboldi, Manuela ;
Pierotti, Marco Alessandro ;
Daidone, Maria Grazia .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) :601-610
[12]   Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms [J].
Calle, EE ;
Kaaks, R .
NATURE REVIEWS CANCER, 2004, 4 (08) :579-591
[13]   Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers [J].
Castellano, Isabella ;
Allia, Elena ;
Accortanzo, Valeria ;
Vandone, Anna Maria ;
Chiusa, Luigi ;
Arisio, Riccardo ;
Durando, Antonio ;
Donadio, Michela ;
Bussolati, Gianni ;
Coates, Alan S. ;
Viale, Giuseppe ;
Sapino, Anna .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (03) :607-617
[14]   New mechanisms for PRLr action in breast cancer [J].
Clevenger, Charles V. ;
Gadd, Samantha L. ;
Zheng, Jiamao .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2009, 20 (05) :223-229
[15]   Male breast cancer: Is the scenario changing [J].
Contractor K.B. ;
Kaur K. ;
Rodrigues G.S. ;
Kulkarni D.M. ;
Singhal H. .
World Journal of Surgical Oncology, 6 (1)
[16]  
Darbre PD, 2010, ANTICANCER RES, V30, P815
[17]   Sentinel node biopsy in male breast cancer [J].
De Cicco, C ;
Baio, SM ;
Veronesi, P ;
Trifirò, G ;
Ciprian, A ;
Vento, A ;
Rososchansky, J ;
Viale, G ;
Paganelli, G .
NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (02) :139-143
[18]   Fulvestrant in advanced male breast cancer [J].
de la Haba Rodriguez, J. R. ;
Porras Quintela, I. ;
Pulido Cortijo, G. ;
Berciano Guerrero, M. ;
Aranda, E. .
ANNALS OF ONCOLOGY, 2009, 20 (11) :1896-1897
[19]   Aromatase inhibition in male breast cancer patients: biological and clinical implications [J].
Doyen, J. ;
Italiano, A. ;
Largillier, R. ;
Ferrero, J. -M. ;
Fontana, X. ;
Thyss, A. .
ANNALS OF ONCOLOGY, 2010, 21 (06) :1243-1245
[20]  
FARROW JOSEPH H., 1942, SCIENCE, V95, P654, DOI 10.1126/science.95.2478.654